The diagnosis and treatment of multiple myeloma has changed dramatically in the past
decade. The disease definition has been updated to include highly specific biomarkers in …

Multiple myeloma is the most frequent monoclonal gammopathy to involve the kidney;
however, a growing number of kidney diseases associated with other monoclonal …

Multiple myeloma (MM) accounts for 1% of all cancers and $10% of all haematological
malignancies. The incidence in Europe is 4.5–6.0/100 000/year with a median age at …

PURPOSE To provide evidence-based recommendations on the treatment of multiple
myeloma to practicing physicians and others. METHODS ASCO and Cancer Care Ontario …

Purpose The aim of the International Myeloma Working Group was to develop practical
recommendations for the diagnosis and management of multiple myeloma–related renal …

Abstract The European Myeloma Network provides recommendations for the management
of the most common complications of multiple myeloma. Whole body low-dose computed …

Owing to increasing resistance and the limited arsenal of new antibiotics, especially against
Gram-negative pathogens, carefully designed antibiotic regimens are obligatory for febrile …

Purpose We investigated whether bortezomib during induction and maintenance improves
survival in newly diagnosed multiple myeloma (MM). Patients and Methods In all, 827 …

Summary Here, the International Myeloma Working Group (IMWG) updates its clinical
practice recommendations for the management of multiple myeloma-related renal …

Over the past ten years, proteasome inhibition has emerged as an effective therapeutic
strategy for treating multiple myeloma (MM) and some lymphomas. In 2003, Bortezomib …